X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
The Colcrys® (colchicine) brand and generic market had U.S. sales of approximately $491 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health.
Lead Product(s): Colchicine
Therapeutic Area: Rheumatology Product Name: Colchicine-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
Colchicine tablets inhibits the beta tubulin polymerisation, which is indicated for prophylaxis of gout flares in adults and Familial Mediterranean fever (FMF) in adults and children 4 years or older
Lead Product(s): Colchicine
Therapeutic Area: Rheumatology Product Name: Colcrys-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2022
Details:
Gloperba (colchicine) liquid oral solution is a USFDA approved, tubulin inhibitor small molecule drug candidate which is indicated for prophylaxis of gout flares in adults.
Lead Product(s): Colchicine
Therapeutic Area: Rheumatology Product Name: Gloperba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
PKM-01 (colchicine) is an intra-articular combination of a fast-acting anesthetic and a controlled-release form of a powerful anti-inflammatory agent (colchicine). It is being evaluated for the treatment of gout flares.
Lead Product(s): Colchicine,Ropivacaine Hydrochloride
Therapeutic Area: Rheumatology Product Name: PKM-01
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
The collaboration will support clinical research involving the CaRi-Heart technology for coronary inflammation diagnostics and FDA-approved LODOCO (colchicine) tablets for therapeutic intervention.
Lead Product(s): Colchicine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lodoco
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Caristo Diagnostics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 16, 2024
Details:
Colchicine capsule (0.6 mg) is a generic version of Hikma's Mitigare , it is indicated for prophylaxis of gout flares in adults. This is the first generic colchicine capsule approved by USFDA.
Lead Product(s): Colchicine
Therapeutic Area: Rheumatology Product Name: Mitigare-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
LODOCO (colchicine, 0.5 mg tablet) through inhibition of beta-tubulin polymerization which is indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization.
Lead Product(s): Colchicine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lodoco
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
Gloperba is the first liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults and was made available in the United States in 2020.
Lead Product(s): Colchicine
Therapeutic Area: Rheumatology Product Name: Gloperba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Scilex Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 14, 2022
Details:
Topical application of DYV702 significantly reduced pain intensity and duration of acute gout flare with higher overall response rates, faster time to resolution, improvements in physical function and reduction in rescue medication use.
Lead Product(s): DYV702,Colchicine
Therapeutic Area: Rheumatology Product Name: DYV702
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
Colchicine tablets inhibits the beta tubulin polymerisation, which is indicated for prophylaxis of gout flares in adults and Familial Mediterranean fever (FMF) in adults and children 4 years or older
Lead Product(s): Colchicine
Therapeutic Area: Genetic Disease Product Name: Colcrys-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2022
Details:
Myinfla (colchicine 0.5 mg extended-release tablets) inhibits the Beta tubulin polymerisation, which is indicated for the reduction of atherothrombotic events in adult patients with existing coronary artery disease.
Lead Product(s): Colchicine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Myinfla
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
Details:
Health Canada has issued a Notice of Compliance for the prescription drug MYINFLA™ (colchicine 0.5 mg tablets) based on the results of the Montreal Heart Institute (MHI)’s COLCOT clinical trial.
Lead Product(s): Colchicine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Myinfla
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: PENDOPHARM DIVISION OF DE PHARMASCIENCE INC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2021
Details:
CSIR and Laxai Life Sciences have been given the regulatory approval by DCGI to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of clinical outcomes during the treatment of COVID-19 patients.
Lead Product(s): Colchicine,Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: LAXAI Life Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2021
Details:
The COLCORONA study assessed colchicine’s potential to reduce the risk of COVID-19-related complications in outpatients over 40 years of age with at least one risk factor for disease progression.
Lead Product(s): Colchicine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2021
Details:
Gout medication colchicine will be tested in a large UK study looking into potential early-stage COVID-19 treatments and enrollment criteria was widened for the latest arm of the trial.
Lead Product(s): Colchicine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
Details:
COLSTAT clinical trial (Colchicine/Statin for the Prevention of COVID-19 Complications) will combine two broadly available medications, colchicine and rosuvastatin, to help reduce complications in Covid-19 infected patients.
Lead Product(s): Colchicine,Rosuvastatin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
Details:
Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.
Lead Product(s): Colchicine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pharmascience Inc.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2021
Details:
Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.
Lead Product(s): Colchicine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pharmascience Inc.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2020
Details:
Randomised Evaluation of COVid-19 Therapy (RECOVERY) trial will investigate colchicine, a commonly used anti-inflammatory treatment.
Lead Product(s): Colchicine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2020
Details:
The first of these sub analyses simultaneously published in the European Heart Journal reveals that early initiation of low-dose colchicine within the first 3 days after MI significantly reduces the risk of ischemic CV events by 48% as vs placebo on top of standard of care.
Lead Product(s): Colchicine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pharmascience Inc.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
Colchicine, a common drug to treat gout, is being evaluated to treat COVID-19 and shows significant reduction in inflammation and lung injury in pre-clinical studies.
Lead Product(s): Colchicine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Details:
Study will combine and repurpose antivirals and host-directed therapies and to determine safety & efficacy of a combination of drugs (Favipiravir+Colchicine, Umifenovir+Colchicine and Nafamostat+5-ALA) and a control arm with the standard of care in COVID-19 patients.
Lead Product(s): Favipiravir,Colchicine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
COLCORONA aims to determine if colchicine may prevent the major inflammatory storm observed in adults suffering from serious complications linked to COVID-19.
Lead Product(s): Colchicine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2020
Details:
Montreal Heart Institute (MHI) Research Center has received grant to advance its contact-less at home study, investigating colchicine as a potential treatment to reduce severe inflammatory conditions associated with COVID-19, slow disease progression, and save patient lives.
Lead Product(s): Colchicine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: COVID-19 Therapeutics Accelerator
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 12, 2020
Details:
COLCORONA trial to examine whether colchicine can reduce complications associated with COVID-19, slow disease progression, and save patient lives.
Lead Product(s): Colchicine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Montreal Heart Institute (MHI) Research Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 07, 2020
Details:
Researchers at the Montreal Heart Institute aim to recruit 6,000 COVID-19 patients for their COLCORONA study. The dtug is believed to stop cytokine storm.
Lead Product(s): Colchicine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2020
Details:
Gloperba (colchicine oral solution) inhibits the Beta tubulin polymerisation, which is indicated for the prophylaxis of gout flares in adults patients.
Lead Product(s): Colchicine
Therapeutic Area: Rheumatology Product Name: Gloperba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2020
Details:
Colchicine capsules inhibits the beta tubulin polymerisation into microtubules, which is indicated for the prophylaxis of gout flares in adults patients.
Lead Product(s): Colchicine
Therapeutic Area: Rheumatology Product Name: Mitigare-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2020
Details:
Colchicine tablets inhibits the beta tubulin polymerisation, which is indicated for prophylaxis of gout flares in adults and Familial Mediterranean fever (FMF) in adults and children 4 years or older
Lead Product(s): Colchicine
Therapeutic Area: Rheumatology Product Name: Colcrys-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2020
Details:
Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.
Lead Product(s): Colchicine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pharmascience Inc.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
